StocksFundsScreenerSectorsWatchlists
INO

INO - Inovio Pharmaceuticals Inc Stock Price, Fair Value and News

9.68USD-0.52 (-5.10%)Market Closed

Market Summary

INO
USD9.68-0.52
Market Closed
-5.10%

INO Stock Price

View Fullscreen

INO RSI Chart

INO Valuation

Market Cap

226.2M

Price/Earnings (Trailing)

-1.67

Price/Sales (Trailing)

46.49

EV/EBITDA

-1.61

Price/Free Cashflow

-1.81

INO Price/Sales (Trailing)

INO Profitability

EBT Margin

-2776.48%

Return on Equity

-115.14%

Return on Assets

-79.04%

Free Cashflow Yield

-55.12%

INO Fundamentals

INO Revenue

Revenue (TTM)

4.9M

Rev. Growth (Yr)

-17.66%

Rev. Growth (Qtr)

-73.57%

INO Earnings

Earnings (TTM)

-135.1M

Earnings Growth (Yr)

54.09%

Earnings Growth (Qtr)

26.31%

Breaking Down INO Revenue

Last 7 days

-12.2%

Last 30 days

-10.3%

Last 90 days

20.4%

Trailing 12 Months

-2.8%

How does INO drawdown profile look like?

INO Financial Health

Current Ratio

3.6

INO Investor Care

Shares Dilution (1Y)

7.81%

Diluted EPS (TTM)

-6.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202312.3M13.7M4.9M4.9M
20222.7M2.7M11.5M10.8M
20218.3M8.2M7.6M2.8M
20202.6M3.5M3.6M8.9M
201931.8M7.5M6.3M4.1M
201839.3M36.4M33.4M30.5M
201737.6M51.8M41.9M42.2M
201643.5M44.4M32.8M35.4M
201513.3M14.8M37.1M40.6M
201414.4M17.4M9.7M10.5M
20133.9M4.2M12.9M13.5M
20128.4M6.4M4.6M4.1M
20117.9M9.2M10.5M9.8M
201008.1M7.1M6.1M
20090009.1M

Tracking the Latest Insider Buys and Sells of Inovio Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 26, 2024
humeau laurent
sold (taxes)
-19,184
8.16
-2,351
chief scientific officer
Feb 26, 2024
shea jacqueline elizabeth
sold (taxes)
-30,420
8.16
-3,728
chief executive officer
Feb 26, 2024
kies peter
sold (taxes)
-28,282
8.16
-3,466
cfo
Feb 26, 2024
kies peter
acquired
-
-
5,875
cfo
Feb 26, 2024
weiner david b.
acquired
-
-
2,916
-
Feb 26, 2024
humeau laurent
acquired
-
-
5,734
chief scientific officer
Feb 26, 2024
shea jacqueline elizabeth
acquired
-
-
7,731
chief executive officer
Jun 30, 2023
sumner michael john
acquired
-
-
35,000
chief medical officer
Jun 05, 2023
zoth lota s.
sold
-3,192
0.56
-5,700
-
May 16, 2023
zoth lota s.
acquired
-
-
19,000
-

1–10 of 50

Which funds bought or sold INO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 17, 2024
Cedar Brook Financial Partners, LLC
new
-
150,959
150,959
0.03%
Apr 17, 2024
Cedar Brook Financial Partners, LLC
sold off
-100
-115,512
-
-%
Apr 16, 2024
Stratos Wealth Partners, LTD.
sold off
-100
-10,973
-
-%
Apr 15, 2024
THOMPSON INVESTMENT MANAGEMENT, INC.
sold off
-100
-81.00
-
-%
Apr 15, 2024
THOMPSON INVESTMENT MANAGEMENT, INC.
new
-
180
180
-%
Apr 15, 2024
S.A. Mason LLC
sold off
-100
-1,913
-
-%
Apr 12, 2024
AdvisorNet Financial, Inc
sold off
-100
-357
-
-%
Apr 12, 2024
AdvisorNet Financial, Inc
new
-
805
805
-%
Apr 11, 2024
City State Bank
sold off
-100
-1,000
-
-%
Apr 11, 2024
City State Bank
new
-
3,000
3,000
-%

1–10 of 44

Are Funds Buying or Selling INO?

Are funds buying INO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own INO
No. of Funds

Unveiling Inovio Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
7.24%
19,766,042
SC 13G/A
Jan 22, 2024
state street corp
0.32%
871,047
SC 13G/A
Jul 10, 2023
state street corp
0.33%
877,447
SC 13G/A
Jul 07, 2023
blackrock inc.
2.3%
6,086,623
SC 13G/A
Feb 09, 2023
state street corp
12.61%
31,472,352
SC 13G/A
Feb 09, 2023
vanguard group inc
6.83%
17,042,500
SC 13G/A
Jan 24, 2023
blackrock inc.
9.3%
23,284,119
SC 13G/A
Apr 11, 2022
state street corp
10.49%
23,267,928
SC 13G/A
Feb 11, 2022
state street corp
6.32%
13,300,430
SC 13G/A
Feb 01, 2022
blackrock inc.
8.7%
18,244,914
SC 13G/A

Recent SEC filings of Inovio Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Apr 17, 2024
424B5
Prospectus Filed
Apr 17, 2024
8-K
Current Report
Apr 15, 2024
ARS
ARS
Apr 11, 2024
DEF 14A
DEF 14A
Mar 06, 2024
10-K
Annual Report
Feb 28, 2024
4
Insider Trading
Feb 28, 2024
4
Insider Trading
Feb 28, 2024
4
Insider Trading
Feb 28, 2024
4
Insider Trading
Feb 28, 2024
4
Insider Trading

Peers (Alternatives to Inovio Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
38.7B
6.8B
-1.66% -28.18%
-8.22
5.66
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.2B
1.8B
-2.46% -28.84%
-41.3
9.94
76.23% 61.08%
16.7B
2.4B
4.57% -8.46%
99.75
6.91
15.42% 18.43%
11.8B
3.7B
-10.11% -29.11%
19.67
3.18
8.87% 75.42%
MID-CAP
5.7B
396.6M
-14.37% -42.33%
-10.84
14.45
425.83% 18.94%
4.4B
-
-13.59% 50.21%
-6.66
60.35
54.84% -34.79%
3.2B
270.6M
-13.81% -4.67%
-13.46
11.9
440.80% -27.84%
2.8B
726.4M
-9.91% -15.82%
-45.19
3.81
40.45% 71.62%
2.8B
240.7M
-20.67% -25.33%
-9.33
12.18
-1.03% -92.09%
SMALL-CAP
1.8B
398.2M
-10.64% -8.42%
24.94
4.47
85.90% -14.05%
558.4M
983.7M
-17.39% -51.52%
-1.02
0.57
-50.36% 17.16%
409.4M
881.7K
-0.38% 387.14%
-9.18
466.16
-77.61% -5.33%
226.2M
4.9M
-10.29% -2.81%
-1.67
46.49
-54.97% 51.71%
6.0M
2.1M
59.81% 33.59%
-0.22
2.14
-13.45% 66.37%

Inovio Pharmaceuticals Inc News

Latest updates
MarketWatch18 Apr 202409:30 pm
Seeking Alpha16 Apr 202411:48 am

Inovio Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-73.6%102,651388,4462,168,2332,207,171124,6669,154,133857,667669,814839,115291,698928,111769,2375,580,581896,7101,067,3991,327,274279,488866,863135,6742,829,9052,502,624
Operating Expenses-23.5%27,496,39135,941,45837,267,06844,067,12156,070,82144,911,177104,921,72171,932,069106,347,45460,244,85283,474,75952,925,61234,920,01936,565,61833,448,08526,559,54230,700,54124,818,65028,336,36731,364,91732,001,788
  S&GA Expenses3.2%10,243,3419,925,05513,523,09813,890,61013,950,94411,824,04748,456,83615,953,45814,048,63513,156,18312,666,34113,881,1948,617,45810,110,50611,071,5107,448,3548,696,5865,681,4415,850,1016,975,0295,636,141
  R&D Expenses11.3%17,253,05015,503,03223,743,97030,176,51142,119,87733,087,13056,464,88555,978,61192,298,81947,088,66970,808,41839,044,41826,302,56126,455,11222,376,57519,111,18822,003,95519,137,20922,486,26624,389,88826,365,647
EBITDA Margin17.8%-26.98-32.81-12.01-19.18-25.24-28.21-130-117-105-28.19-16.00-20.98---------
Interest Expenses-9.9%282,325313,488313,488313,488313,488313,488313,488313,488480,313476,374466,726513,0341,068,0081,984,0462,846,6412,803,7552,668,8372,428,6712,194,783656,248-156,261
Income Taxes------------------87,764--106,771-62,800-
Earnings Before Taxes26.3%-25,003,638-33,929,864-35,534,533-40,649,317-54,463,139-37,783,896-108,497,311-76,908,506-106,947,580-60,169,041-82,139,958-53,967,744-22,415,20120,931,010-128,270,709-33,135,404-38,235,146-23,536,452-29,685,847-29,351,667-32,962,205
EBT Margin17.5%-27.76-33.67-12.34-19.56-25.69-28.66-132-119-107-28.89-16.83-22.10---------
Net Income26.3%-25,003,638-33,929,864-35,534,533-40,649,317-54,463,139-37,783,896-108,497,311-79,073,719-106,947,580-60,169,041-82,139,958-54,402,131-24,338,38019,171,336-129,172,466-33,135,404-37,662,038-23,090,693-29,387,226-29,219,262-32,962,205
Net Income Margin17.5%-27.76-33.66-12.33-19.55-25.89-28.84-133-120-107-29.20-17.34-22.70---------
Free Cashflow9.7%-26,275,785-29,110,632-32,338,571-36,961,461-36,505,141-67,552,146-51,245,185-61,882,102-38,534,821-46,659,317-78,667,141-53,078,252---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-11.5%171193233267349392459446496536592655540438443339144152165191131
  Current Assets-12.4%15317520323431535041640044848754258847137738227694.0099.0011113588.00
    Cash Equivalents-23.9%14.0019.0053.0028.0046.0022.0041.0059.0071.0068.0059.0084.0025117921515822.0016.0020.0021.0024.00
  Net PPE-11.9%5.006.006.007.008.0016.0016.0017.0017.0018.0018.0011.0011.0011.0011.0012.0013.0014.0014.0015.0016.00
  Goodwill---11.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.00
Liabilities-2.4%54.0055.0064.0067.0012612516290.0096.0082.0083.0073.0079.0011425715113911510911044.00
  Current Liabilities-2.6%43.0044.0052.0055.0097.0095.0013159.0066.0051.0052.0042.0042.0041.0038.0032.0032.0020.0024.0027.0035.00
  Long Term Debt-----17.0016.0017.0016.0015.0014.0015.0014.005.004.0014.0013.0064.008.0063.0061.00-
    LT Debt, Current1.7%17.0016.0017.0016.00-----------------
    LT Debt, Non Current-----17.00----------------
Shareholder's Equity-15.1%1171381691992222672983554004545095824613241861885.0036.0056.0081.0087.00
  Retained Earnings-1.4%-1,622-1,600-1,600-1,500-1,487-1,433-1,395-1,287-1,209-1,102-1,042-960-906-881-901-772-739-702-679-649-620
  Additional Paid-In Capital0.3%1,7411,7371,7341,7281,7111,7011,6941,6421,6101,5571,5511,5421,3671,2061,088958743735732727708
Shares Outstanding3.7%23.0022.0022.0022.0021.0021.0020.0018.0017.0017.0017.0017.00---------
Minority Interest--------------0.000.004.002.002.003.003.000.00
Float---120---426---1,900---4,200---280--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations9.7%-26,275-29,110-32,314-36,664-36,340-67,465-50,527-61,882-37,891-46,490-78,459-52,867-51,216-74,158-27,151-25,452-13,737-27,733-23,924-32,454-17,281
  Share Based Compensation9.0%2,2662,0792,9183,8093,2743,2348,3367,7115,4745,6205,6469,5963,8254,1583,6624,0022,0342,0803,3553,4332,138
Cashflow From Investing463.0%19,943-5,49353,90719,00054,00144,557-10,30421,332-6,49355,95850,306-275,115-3,71639,115-42,385-51,80810,4358,27021,588-49,3377,183
Cashflow From Financing163.1%1,8386992,883-4246,6683,81242,93928,42247,595-4403,441160,903126,939-1,695126,523213,5139,64515,5811,29478,87714,394

INO Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues [Abstract]   
Revenue from collaborative arrangements and other contracts, including affiliated entity$ 832,010$ 10,262,268$ 1,774,758
Operating expenses:   
Research and development86,676,563187,650,503249,240,324
General and administrative47,582,10490,185,28553,752,353
Impairment of goodwill10,513,37100
Total operating expenses144,772,038277,835,788302,992,677
Loss from operations(143,940,028)(267,573,520)(301,217,919)
Other income (expense):   
Interest income8,133,2904,782,0303,363,080
Interest expense(1,222,789)(1,253,952)(1,936,447)
Gain (loss) on investment in affiliated entity773,145(1,899,654)(553,570)
Net unrealized gain (loss) on available-for-sale equity securities5,850,626(7,846,172)(3,222,838)
Other (expense) income, net(4,711,596)(3,861,584)343,371
Net loss before share in net loss of Geneos(135,117,352)(277,652,852)(303,224,323)
Share in net loss of Geneos0(2,165,213)(434,387)
Net loss$ (135,117,352)$ (279,818,065)$ (303,658,710)
Net loss per share   
Basic (in dollars per share)[1]$ (6.09)$ (14.07)$ (17.45)
Diluted (in dollars per share)[1]$ (6.09)$ (14.07)$ (17.45)
Weighted average number of common shares outstanding   
Basic (in shares)[1]22,173,66219,885,18217,402,483
Diluted (in shares)[1]22,173,66219,885,18217,402,483
[1]
(1) Share and per share amounts have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.

INO Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 14,310,862$ 46,329,359
Short-term investments130,982,913206,669,397
Prepaid expenses and other current assets5,393,66550,130,481
Prepaid expenses and other current assets from affiliated entities20,432375,227
Total current assets153,113,100315,242,680
Fixed assets, net4,960,9867,727,997
Investments in affiliated entity2,780,2872,007,142
Intangible assets, net02,129,861
Goodwill010,513,371
Operating lease right-of-use assets9,491,73510,228,207
Other assets605,315684,044
Total assets170,951,423348,533,302
Current liabilities:  
Accrued clinical trial expenses2,365,38210,594,073
Operating lease liability2,406,5222,803,973
Grant funding liability87,4892,475,031
Grant funding liability from affiliated entities21,91887,673
Convertible senior notes16,770,6540
Total current liabilities42,570,22896,868,074
Convertible senior notes016,614,840
Operating lease liability, net of current portion11,032,06612,655,586
Deferred tax liabilities032,046
Total liabilities53,602,294126,170,546
Commitments and contingencies
Inovio Pharmaceuticals, Inc. stockholders’ equity:  
Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2023 and 202200
Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2023 and 2022, issued and outstanding: 22,793,075 at December 31, 2023 and 21,090,938 at December 31, 2022[1]22,79221,090
Additional paid-in capital1,740,954,0741,710,888,191
Accumulated deficit(1,622,965,136)(1,487,847,784)
Accumulated other comprehensive loss(662,601)(698,741)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity117,349,129222,362,756
Total liabilities and stockholders’ equity170,951,423348,533,302
Nonrelated Party  
Current assets:  
Accounts receivable01,701,726
Current liabilities:  
Accounts payable and accrued expenses19,847,74479,686,885
Related Party  
Current assets:  
Accounts receivable2,405,22810,036,490
Current liabilities:  
Accounts payable and accrued expenses$ 1,070,519$ 1,220,439
[1]
(1) The Company effected a reverse stock split of its outstanding shares of common stock on January 24, 2024 where every twelve shares of its common stock issued and outstanding was converted into one share of common stock.Any fractional post-split shares as a result of the reverse split were paid in cash. Shareholders of the Company authorized the Board of Directors to approve the reverse stock split at a special meeting of stockholders held on January 12, 2024.Outstanding share amounts have been restated to reflect the reverse stock split on a retroactive basis for all periods presented.
INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
 CEO
 WEBSITEinovio.com
 INDUSTRYBiotechnology
 EMPLOYEES135

Inovio Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Inovio Pharmaceuticals Inc? What does INO stand for in stocks?

INO is the stock ticker symbol of Inovio Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inovio Pharmaceuticals Inc (INO)?

As of Fri Apr 19 2024, market cap of Inovio Pharmaceuticals Inc is 226.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INO stock?

You can check INO's fair value in chart for subscribers.

What is the fair value of INO stock?

You can check INO's fair value in chart for subscribers. The fair value of Inovio Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Inovio Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Inovio Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether INO is over valued or under valued. Whether Inovio Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Inovio Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INO.

What is Inovio Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, INO's PE ratio (Price to Earnings) is -1.67 and Price to Sales (PS) ratio is 46.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Inovio Pharmaceuticals Inc's stock?

In the past 10 years, Inovio Pharmaceuticals Inc has provided -0.227 (multiply by 100 for percentage) rate of return.